PPCB Earnings Propanc Biopharma, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–16 of 16
| Q3 2026 | 2026-03-31 | -0.95 | 2026-05-14 | 10-Q |
| Q2 2026 | 2025-12-31 | -0.69 | 2026-02-17 | 10-Q |
| Q1 2026 | 2025-09-30 | -0.39 | 2025-11-14 | 10-Q |
| FY 2025 | 2025-06-30 | -14.85 | 2025-09-29 | 10-K |
| Q3 2026 | 2025-03-31 | -38.62 | 2026-05-14 | 10-Q |
| Q2 2026 | 2024-12-31 | -67.65 | 2026-02-17 | 10-Q |
| Q1 2026 | 2024-09-30 | -35.97 | 2025-11-14 | 10-Q |
| FY 2025 | 2024-06-30 | -1420.53 | 2025-09-29 | 10-K |
| Q3 2025 | 2024-03-31 | -3164.41 | 2025-05-15 | 10-Q |
| Q2 2025 | 2023-12-31 | -3835.55 | 2025-02-14 | 10-Q |
| Q1 2025 | 2023-09-30 | -0.04 | 2024-11-14 | 10-Q |
| FY 2024 | 2023-06-30 | -1.80 | 2024-09-30 | 10-K |
| Q3 2024 | 2023-03-31 | -2.08 | 2024-05-15 | 10-Q |
| Q2 2024 | 2022-12-31 | -2.10 | 2024-02-20 | 10-Q |
| Q1 2024 | 2022-09-30 | -2.13 | 2023-11-14 | 10-Q |
| FY 2023 | 2022-06-30 | -49.23 | 2023-09-28 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.